Zometa improves survival in Phase III trial in multiple myeloma
This article was originally published in Scrip
Executive Summary
Novartis's bisphosphonate Zometa (zoledronic acid) has become the first drug of its class to improve overall survival in multiple myeloma (MM) in combination with standard treatment in a Phase III trial, lending further credence to the belief that it has an anticancer effect in addition to its beneficial effects on bone.